Samsung Medical Center
Seoul, 06351, South Korea
Location status: Recruiting
NCT Number: NCT06181929
This is a single-arm prospective pilot study in a single institution. The target accrual is 200 participants of Korean, female sex, never smoker status, and family history of lung cancer. The study will aim to enroll 200 participants in two years.
Interested in participating?
Request Info45 year–74 year
Female
Interventional
Not applicable
Seoul, 06351, South Korea
Location status: Recruiting
Interested individuals will contact a research coordinator who will help to assess for study eligibility. Individuals who are eligible and able to sign informed consent will then proceed to have a LDCT screening exam with a result reported by a radiologist approved to read lung cancer screening scans. Results of this screening test will be discussed with the subject and further recommendations will be given. Negative results will proceed to have repeat LDCT exams for two additional years. Positive results will be recommended to have further diagnostic work-up, and possible treatment. Those with positive findings may be recommended to repeat a LDCT at varied intervals (e.g. at 3 months, at 6 months, etc.) per Lung-RADS recommendations which can be conducted as a research LDCT or as standard-of-care.
In addition, blood draw collection for a plasma-based assay will be collected at baseline, first year and second year for all patients along with the repeated LDCT scans.
A medical history questionnaire containing questions regarding ethnicity, family history of lung cancer, environmental exposures including secondhand smoke exposure, and a residential district to estimate the exposure of PM2.5 or PM10 will be given to the patient at the initial visit after informed consent has been obtained (Appendix A). Questionnaire can be collected within 1 month from the baseline consent.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A subject can voluntarily discontinue active screening with LDCTs after the baseline LDCT is completed but will remain in study follow-up with follow-up calls in 12-month intervals for up to 10 years since initial consent
Time frame: up to 2years
detection rate
Time frame: up to 2years
Whether lung cancer is found in each screening test conducted for the first (baseline) and first and second years
Time frame: up to 2years
number of lung cancer diagnosed, number of stage I, rate of surgery, rate of false positive
Time frame: up to 2years
cfDNA
Time frame: up to 2years
EGFR mutation
Contact information is provided by the study sponsor or research team.
Kyungmi Park
CONTACT
Um Sang-Won, PhD
CONTACT
Sang-Won Um
Other
A Prospective Study for the Early Diagnosis of Lung Cancer in Korean Females Who Are Never Smoker with a Family History of Lung Cancer
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07441603
Alcohol Drinking, Alcohol Use
Greifswald, Germany
View Trial DetailsNCT07032480
Behavior, Health Behavior
Istanbul, Üsküdar, Turkey (Türkiye)
View Trial DetailsNCT05665179
Alcohol Use Disorder, Alcohol-Related Disorders
Ann Arbor, Michigan, United States
View Trial DetailsNCT04164940
Alcohol Consumption, Alcohol Dependence
Stavanger, Norway
View Trial Details